Subscribe to Search results

Lord Glenarthur was not aware of the CSM(B)'s 13th July meeting regarding AIDs.

Published on:

Lord Kenneth Clarke was not aware of the CSM(B)'s existence and was surprised Lord Simon Glenarthur was unaware of the CSM(B) meetings and deliberations.

Published on:

Professor Richard Tedder stated in his statement to the Inquiry ""Personally, I would have recalled, prevented or very strictly controlled the use of imported commercial blood products, especially those from the USA, which were known to have a significant risk over and above the expected. If the same was to occur with a British product, then clearly recall would be appropriate. At the Middlesex we would only have used such products if it was the only option to avoid serious harm to a patient".

Published on:

Professor Tedder emphasized in his oral evidence that the use of prisoners for donated blood, particularly in the US, meant that the producer of the product would not know their donor.

Published on:

In a minute from Dr Smith to Dr Lane, it was suggested that importation of US concentrate should cease on the ground of the risk of hepatitis alone.

Published on:

At a meeting of the Reference Centre Directors it was agreed that for young children, and those who were newly diagnosed with haemophilia, cryoprecipitate was to be used. Next preference was to be given to NHS factor concentrate.

Published on:

At a meeting of the CSM(B), it was stated that clotting concentrates were "life-saving" for haemophiliacs and the risk of AIDs was considered small. It was concluded that withdrawal of clotting factor concentrates from the market was not feasible on the grounds of supply.

Published on:

A hierarchy of safety used by the UKHCDO was implemented meaning that for those newly diagnosed with haemophilia, cryoprecipitate was used. Preference was then given to NHS Factor concentrate with US Factor concentrate given as a last resort.

Published on:

Dr Biggs stated that "Cryoprecipitate is a simple concentrate made from plasma at all Regional Transfusion Centres. Cryoprecipitate is much superior to plasma for the treatment of haemophilia A patients but the material is very variable from one sample to another and the potency cannot be known before it is used. For each dose the assumption must be made that the material is of low potency thus there is a tendency to use more material for each patient than is probably needed."

Published on:

Donations were tested for HTLV-3 at Oxford from this date with a temporal scope of six (rather than the national standard of five) years.

Published on:

Dr Craske expressed concern that he did not know the outcome of patients who had received Factor VIII from batch HL3186 and other batches which might have contained HIV.

Published on:

Four blood donations by a donor who showed symptoms of AIDS were identified.

Published on:

Recall arrangements in respect of batch HL3186 were instituted in Cardiff.

Published on:

The Blood Products Laboratory requested a lookback in relation to some batches of Factor 8. Dr Jayaswal, consultant haematologist at Wessex RTC, advised "Logistically it is going to be impossible for us to scrutinize 1500 donors from so long ago".

Published on:

Dr Lane of the Blood Products Laboratory chased a lookback exercise involving Wessex RTC and highlighted that the Factor 8 batches related to a potential HIV seroconversion in a young person with haemophilia.

Published on:

Dr Smith agreed to check the records at Wessex RTC to see if any HIV 1 antibody positive donors were implicated in batch 8CRV1526.

Published on:

Dr Gunson reported to a meeting of the regional transfusion directors on the plan to be adopted when a patient was diagnosed with AIDS and had donated or received blood or blood products.

Published on:

The terms of reference for the Advisory Committee on the National Blood Transfusion Service Working Group on AIDS were "To consider the implications for the National Blood Transfusion Service of testing blood donations for antibody to HTLV III and to report."

Published on:

During a meeting of regional transfusion directors it was noted that when tracing the recipients of donations from a HIV-positive donor, finding that a recipient had died was "not necessarily the end of the story" as the recipient's organs may have been used for transplantation.

Published on:

The working party of the Regional Transfusion Directors' Committee produced a report on the screening of blood donations for anti-HTLV-3 in regional blood transfusion centres. Procedures for testing donations were set out in full as well as the follow-up for HTLV-3 positive donations.

Published on: